The adoptive transfer of T cells redirected to tumor-associated antigens via transgenic
expression of chimeric antigen receptors (CARs) has produced tumor responses, even in …

The adoptive transfer of genetically engineered T cells expressing chimeric antigen
receptors (CARs) has emerged as a transformative cancer therapy with curative potential …

Broader implementation of cell-based therapies has been hindered by the logistics
associated with the expansion of clinically relevant cell numbers ex vivo. To overcome this …

The use of chimeric antigen receptor (CAR)–modified T cells as a therapy for hematologic
malignancies and solid tumors is becoming more widespread. However, the infusion of a T …

The adoptive transfer of chimeric antigen receptor (CAR)–modified T cells has produced
tumor responses even in patients with refractory diseases. However, the paucity of antigens …

Background The adoptive transfer of T cells redirected to tumor via chimeric antigen
receptors (CARs) has produced clinical benefits for the treatment of hematologic diseases …

Background Successful targeting of solid tumors such as breast cancer (BC) using chimeric
antigen receptor (CAR) T cells has proven challenging, largely attributed to the …

Collagen I, the most abundant protein in humans, is ubiquitous in solid tumors where it
provides a rich source of exploitable metabolic fuel for cancer cells. While tumor cells were …

The majority of clinically approved drugs target proteins that are secreted or cell surface
bound. However, further advances in this area have been hindered by the challenging …

T-cell immunotherapy has demonstrated remarkable clinical outcomes in certain
hematologic malignancies. However, efficacy in solid tumors has been suboptimal, partially …